Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS

Genzyme Europe

Apellis Europe B.V.

Genzyme Europe patent portfolio — 24 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA HQ
1981 Founded
273 Employees
Public company Type
APLS · NYSE Ticker
Company details
Status
Public
HQ
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
Founded
1981
Employees
273
Programs
20
Drugs
5
Patents
24
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Genzyme Europe patents

24 pharmaceutical patents indexed for Genzyme Europe. 0 expire within 24 months.

Genzyme Europe has 24 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

24 patents

Patent portfolio

  1. US 12290566

    Dosing regimens and related compositions and methods

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12251395

    RNAS for complement inhibition

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11903994

    Dosing regimens

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11844841

    Dosing regimens and related compositions and methods

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11712460

    Methods of treating chronic disorders with complement inhibitors

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11661441

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11510939

    RNAs for complement inhibition

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11407789

    Cell-penetrating compstatin analogs and uses thereof

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11338013

    Combination therapy for C3 inhibition

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11291407

    Detection of high risk drusen

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11292815

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11040107

    Dosing regimens and related compositions and methods

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11013782

    Methods of treating chronic disorders with complement inhibitors

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11001610

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10941184

    Cell-penetrating compstatin analogs and uses thereof

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10875893

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10696718

    Compstatin analogs for treatment of neuropathic pain

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10407466

    Methods of selecting compstatin mimetics

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10308687

    Cell-penetrating compstatin analogs and uses thereof

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10125171

    Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10039802

    Methods of treating chronic disorders with complement inhibitors

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10035822

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9421240

    Compstatin analogs for treatment of neuropathic pain

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8580735

    Local complement inhibition for treatment of complement-mediated disorders

    Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Genzyme Europe have?

24 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Genzyme Europe patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.